VTVT vTv Therapeutics

vTv Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

vTv Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

HIGH POINT, N.C., Dec. 02, 2019 (GLOBE NEWSWIRE) -- (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and Alzheimer’s disease, today announced that it is scheduled to present a general company update at the 31st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019 at 10:50 a.m. Eastern Time in New York City. Company management will also be meeting with members of the investment community during one-on-one meetings at the conference.

A live webcast of the presentation can be accessed and will be accessible for 30 days following the presentation at .

About vTv Therapeutics

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment of type 1 diabetes, Alzheimer’s disease, and inflammatory disorders. vTv’s development partners are pursuing additional indications in type 2 diabetes, COPD, and genetic mitochondrial diseases.

Contacts

Investors:

vTv Therapeutics Inc.

or



Media:

Glenn Silver

Lazar FINN Partners

646-871-8485

EN
02/12/2019

Underlying

VTVTvTv Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on vTv Therapeutics

 PRESS RELEASE
Free
VTVT vTv Therapeutic...

vTv Therapeutics and M42’s IROS Announce Submission of Phase 2 Clinica...

vTv Therapeutics and M42’s IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health Trial to assess cadisegliatin as potential adjunctive therapy to insulin in patients with T2D HIGH POINT, N.C., Dec. 18, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced a Phase 2 clinical study protocol developed in collaboration with M42’s Insights Research Organization & Solutions (IROS), a leading United Arab Emirates (UAE)-based contract resea...

December 18, 2025 1 EN
 PRESS RELEASE
Free
VTVT vTv Therapeutic...

vTv Therapeutics Reports Third Quarter 2025 Financial Results and Prov...

vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Topline Phase 3 CATT1 data for cadisegliatin in type 1 diabetes expected second half 2026  $80 million private placement strengthens balance sheet and supports Phase 3 CATT1 completion Announced issuance of new U.S. patent covering crystalline salts and co-crystals forms of cadisegliatin with exclusivity expected out to 2041 HIGH POINT, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliati...

November 6, 2025 1 EN
 PRESS RELEASE
Free
VTVT vTv Therapeutic...

vTv Therapeutics Announces New Appointments to its Scientific Advisory...

vTv Therapeutics Announces New Appointments to its Scientific Advisory Board Board to offer guidance on clinical development of cadisegliatin for type 1 diabetes as company has initiated Phase 3 trials HIGH POINT, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, today announced the appointment of Alfonso Galderisi, MD, PhD, Mark Evans, MD, Chantal Mathieu, MD, PhD, and Klara Klein, MD, PhD, to its Scientific Advisory Board (SAB). The SAB, composed of internationally recognize...

October 9, 2025 1 EN
 PRESS RELEASE
Free
VTVT vTv Therapeutic...

vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61s...

vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting Company to share new independent research on TTP-RA, vTv’s oral RAGE antagonist HIGH POINT, N.C., Sept. 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced that the company will present information on two of its investigational small molecules for type 1 diabetes (T1D) at the INNODIA Symposium during the European Association for the Study of Diabetes (EASD) 61st Annual Meeting. INNODIA is an international non-for-profit organizatio...

September 15, 2025 1 EN
 PRESS RELEASE
Free
VTVT vTv Therapeutic...

UPDATE -- vTv Therapeutics to Participate in Upcoming September Invest...

UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following September investor conferences: H.C. Wainwright 27th Annual Global Investment ConferenceDate:Tuesday, September 9, 2025Format:1x1 Investo...

September 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch